Drug Profile
ABBV 47D11
Alternative Names: 47D11 - AbbVie/Harbor Biomed/Erasmus University Medical Center/University of Utrecht; ABBV-47D11; Anti-coronavirus antibody - AbbVie/Harbor Biomed/Erasmus University Medical Center/University of Utrecht; HBM-9022Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Erasmus MC; Harbour BioMed; Utrecht University
- Developer AbbVie; Erasmus MC; Harbour BioMed; Utrecht University
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Hungary (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Israel (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Netherlands (IV, Infusion)